FDA grants Fast Track designation for DiscGenics' cell therapy for disc generation

Spinal Tech
Alan Condon -

DiscGenics received FDA Fast Track designation for its investigational cell therapy for the reduction in pain and disability linked with degenerative disc disease.

Three insights:

1. IDCT is an injectable cell therapy that use progenitor cells — known as Discogenic Cells — to provide a regenerative solution for the treatment of mild to moderate degenerative disc disease.

2. Its biomedically engineered progenitor cells are derived from intervertebral disc tissue and offer a non-invasive approach to treating the condition.

3. IDCT is currently being evaluated in clinical trials in the U.S. and Japan.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.